Imaging techniques to improve treatment of heart rhythm disorders
Peri-Procedural Transmural Electrophysiological Imaging of Scar-Related Ventricular Tachycardia
NA · Nova Scotia Health Authority · NCT03713866
This study is testing if advanced imaging techniques can help doctors better treat heart rhythm problems in patients who have had a heart attack.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Nova Scotia Health Authority (other) |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT03713866 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of advanced imaging techniques to enhance the treatment of ventricular tachycardia (VT) in patients with myocardial infarction. It aims to integrate functional VT data with 3D imaging from CT or MRI to better visualize the electrical circuits involved in VT. A total of 40 patients referred for catheter ablation will undergo noninvasive imaging and stimulation studies before and after the ablation procedure. The goal is to improve the identification of ablation targets and assess the outcomes of the treatment.
Who should consider this trial
Good fit: Ideal candidates are patients with a history of sustained monomorphic ventricular tachycardia who have been referred for catheter ablation and have a previously implanted ICD.
Not a fit: Patients with severe renal impairment, life expectancy under six months, or contraindications to catheter ablation will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective ablation procedures and improved outcomes for patients with scar-related ventricular tachycardia.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for cardiac conditions, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * One or more episodes of sustained monomorphic VT * Referred for catheter ablation * Previously implanted ICD * Signed the patient informed consent form * Able and willing to comply with all pre-, post-, and follow-up testing and requirements Exclusion Criteria: * Have estimated Glomerular Filtration Ratio (eGFR) less than 30 * Have a life expectancy less than 6 months or are listed for heart transplantation at time of inclusion * Are pregnant * Are on IV inotropic agents * Have any contraindication to catheter ablation (including but not limited to mechanical prosthetic aortic and mitral valves, known protruding Left Ventricular (LV) thrombus * New York Heart Association (NYHA) functional class IV * Had ST wave elevation myocardial infarction within \< 1 month * Unwilling or unable to undergo cardiac MRI scan AND unwilling or unable to undergo cardiac CT scan (e.g. contrast allergy).
Where this trial is running
Halifax, Nova Scotia
- QEII HSC — Halifax, Nova Scotia, Canada (RECRUITING)
Study contacts
- Principal investigator: John L Sapp, MD FRCPC — Nova Scotia Health Authority
- Study coordinator: John L Sapp, MD FRCPC
- Email: john.sapp@nshealth.ca
- Phone: 902 473 4272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ventricular Tachycardia, Myocardial Infarction